
Opinion|Videos|January 17, 2024
The Current Treatment Landscape in CLL With the Advent of Novel Therapy Agents
Author(s)Mazyar Shadman, MD, MPH
Dr Mazyar Shadman reviews emerging targeted therapies shaping the treatment landscape and optimal sequencing in CLL.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Subcutaneous Amivantamab for EGFR-Mutated NSCLC Indications
2
Enfortumab Vedotin Plus Pembrolizumab Improves Survival in MIBC
3
Long-Term ECHO Data Support Concurrent Acalabrutinib/BR in MCL
4
FDA Grants Regular Approval to Rucaparib for BRCA-Mutated mCRPC
5








































